A Phase II Study of Oral LDE225 in Patients With Hedge-Hog (Hh)-Pathway Activated Relapsed Medulloblastoma (MB)
Public ClinicalTrials.gov record NCT01708174. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase II, Multi-center, Open-label, Single-arm Study of the Efficacy and Safety of Oral LDE225 in Patients With Hh-pathway Activated Relapsed Medulloblastoma
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This Phase II study evaluated the safety and efficacy of LDE225 in adult and pediatric patients with Hh-pathway activated, relapsed MB.
Study identification
- NCT ID
- NCT01708174
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 22 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 4 Months and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- May 5, 2013
- Primary completion
- Oct 4, 2016
- Completion
- Oct 4, 2016
- Last update posted
- Aug 10, 2017
2013 – 2016
United States locations
- U.S. sites
- 8
- U.S. states
- 8
- U.S. cities
- 8
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Ann & Robert H. Lurie Children Dept of Oncology | Chicago | Illinois | 60611 | — |
| Sidney Kimmel Comprehensive Cancer Center/Johns Hopkins Med. Dept Onc | Baltimore | Maryland | 21231 | — |
| Dana Farber Cancer Institute SC-7 | Boston | Massachusetts | 02215 | — |
| Columbia University Medical Center- New York Presbyterian Dept of Oncology | New York | New York | 10032 | — |
| Cincinnati Children's Hospital Medical Center Division of Hema/Onco. | Cincinnati | Ohio | 45229-3039 | — |
| Children's Hospital of Pittsburgh Dept of Oncology | Pittsburgh | Pennsylvania | 15213-2583 | — |
| University of Texas/MD Anderson Cancer Center SC-3 | Houston | Texas | 77030-4009 | — |
| Seattle Cancer Care Alliance Dept Oncology | Seattle | Washington | 98105 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 33 non-U.S. sites.
Recently updated Medulloblastoma trials
Other public records listing Medulloblastoma. Sorted by last update posted; newest first. Not a recommendation.
- NCT05057702: Individualized Treatment Plan in Children and Young Adults With Relapsed Medulloblastoma and Ependymoma Recruiting
- NCT06701812: Digoxin Medulloblastoma Study Recruiting
- NCT02875314: HeadStart4: Newly Diagnosed Children (<10 y/o) With Medulloblastoma and Other CNS Embryonal Tumors Active, not recruiting
- NCT07346157: Liothyronine in Combination With BIT Regimen for Medulloblastoma With or Without Minimal Residual Disease Not yet recruiting
- NCT06161519: PLX038 in Primary Central Nervous System Tumors Containing MYC or MYCN Amplifications Recruiting
- NCT04337177: Flavored, Oral Irinotecan VAL-413 (Orotecan®) Given With Temozolomide for Treatment of Recurrent Pediatric Solid Tumors Active, not recruiting
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT01708174, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Aug 10, 2017 · Synced Sep 1, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT01708174 live on ClinicalTrials.gov.